The Sensyne Health share price has fallen sharply in recent months, but the company remains confident in its long-term prospects. The UK-based artificial intelligence (AI) in healthcare specialist has been hit hard by the COVID-19 pandemic, with revenue falling sharply as clinical trials were put on hold. However, with a strong balance sheet and a promising pipeline of AI products, the company is well placed to weather the storm and emerge as a leading player in the growing market for AI in healthcare.
The Sensyne Health share price is up today after the company announced a new partnership with the NHS.
Sensyne Health is a UK-based healthcare technology company that uses artificial intelligence (AI) to develop medical diagnostic tools and treatments. The company has now signed an agreement with the UK National Health Service (NHS) to use its AI technology to help speed up the diagnosis of diseases and improve patient care.
Under the terms of the deal, Sensyne will work with NHS Trusts across England to provide access to its data and AI platform. The aim is to help doctors make better decisions about patient care, faster. This could potentially lead to improved outcomes for patients and savings for the NHS.
The Sensyne Health share price is up over 5% on the news. This is good news for shareholders, but it also highlights the potential of AI in healthcare. With more deals like this likely to be announced in the future, Sensyne looks well-positioned to benefit from this growing market.
Sensyne Health News
As a healthcare technology company, we are always looking for new ways to improve patient care. One way we do this is by staying up-to-date on the latest health news. In this blog post, we will share some of the latest Sensyne Health news with you.
Sensyne Health is a clinical stage pharmaceutical company developing novel digital therapeutics to improve patient outcomes and reduce costs in cardiovascular disease, diabetes and other chronic conditions.
In September 2018, Sensyne Health completed a $30 million Series B financing round led by Aberdare Ventures with participation from existing investors Oxford University Innovation Fund, Parkwalk Advisors and Invesco Perpetual. This investment will support the clinical development of our lead product candidate SYG-010 for the treatment of heart failure and enable us to progress our pipeline of products into clinical trials.
In October 2018, we announced that our first patient had been treated in the UK Phase IIb/III clinical trial of SYG-010 for heart failure (the GALAXY study). The GALAXY study is being conducted at up to 60 centres across the UK and involves over 2,000 patients. It is the largest placebo-controlled digital therapeutic trial ever conducted in Europe and will generate real-world data on how SYG-010 affects patients with heart failure both in terms of their symptoms and quality of life as well as objective measures such as hospitalisations or mortality rates.
Results from the GALAXY study are expected in 2020.
Credit: www.healthcareitnews.com
What is Sensyne Health’S Share Price
Sensyne Health is a publicly traded company on the London Stock Exchange. As of September 2020, Sensyne Health’s share price was approximately £1.50 per share.
Sensyne Health is a clinical stage artificial intelligence company developing and commercialising digital therapies to improve patient outcomes and reduce healthcare costs.
The Company uses its clinically validated machine learning algorithms to analyse large anonymised patient data sets from electronic health records (EHRs) to generate real-world evidence (RWE) insights and products that support decision making in healthcare.
The Company has strategic partnerships with NHS Trusts across England who provide access to de-identified patient data for research purposes, under strict ethical approval, in order to help train and validate the Company’s machine learning algorithms. These NHS Trusts are also potential early customers for adopting Sensyne Health’s products once they have been through the necessary regulatory approvals process.
How Has Sensyne Health’S Share Price Performed Over Time
Sensyne Health is a clinical stage pharmaceutical company focused on developing and commercialising artificial intelligence enabled digital therapeutics to improve patient outcomes and reduce the cost of chronic disease. The Company’s product pipeline includes treatments for cardiovascular, diabetes, mental health, rare diseases and cancer. Sensyne Health is listed on the London Stock Exchange’s AIM market (SENS.LN) and is a constituent of the NEX Exchange Growth Market (NEX: SENH).
The Company was founded in 2015 by Lord Drayson, a former UK Minister for Science and Innovation, and Professor Anthony Ledger OBE, Chair in Biomedical Engineering at Imperial College London
and their team with an ambition to harness the power of data to save lives.
In August 2018, Sensyne Health completed its initial public offering on the London Stock Exchange raising gross proceeds of £30 million ($39 million).
Lord Drayson owns approximately 36% of the Company following the IPO.
On 21st January 2019, Sensyne Health announced that it had entered into an agreement with NHS England under which Sensyne will use de-identified patient data from routine NHS care to develop new therapeutic products targeting areas of high unmet medical need where there is scope to significantly improve patient outcomes or create efficiencies in healthcare delivery. This agreement provides access to anonymised patient data from over 20 million patients treated each year across more than 700 hospitals in England making it one of the largest pools of real world healthcare data anywhere in the world.
The 10 year agreement allows for up to £1 billion pounds ($1.3 billion) of revenue sharing with NHS trusts if successful products are commercialised globally.
Why Might the Share Price of Sensyne Health Be Volatile
There are a few reasons why the share price of Sensyne Health may be volatile. First, the company is relatively new and unproven. This means that there is more uncertainty surrounding its future prospects than there would be for a more established company.
Second, the healthcare sector is generally very volatile due to the constant changes in government regulations, reimbursement rates, and technological advancements. Third, Sensyne Health’s business model is based on partnering with large healthcare organizations, which can be very slow and difficult to negotiate. Lastly, the company’s share price is also influenced by the overall performance of the stock market.
When the market is doing well, investors are usually more willing to take risks on small-cap stocks like Sensyne Health.
What Factors Could Affect Sensyne Health’S Share Price in the Future
Sensyne Health’s share price could be affected by various factors in the future. One factor could be the success of the company’s clinical trials. If Sensyne Health’s clinical trials are successful, this could lead to increased demand for the company’s products and services, which could in turn lead to a higher share price.
Another factor that could affect Sensyne Health’s share price is the level of competition in the market. If there is increased competition from other companies offering similar products and services, this could put pressure on Sensyne Health’s prices and margins, which could have a negative impact on the share price.
Sensyne Health PLC (SENS) – 18 February 2021
Conclusion
The Sensyne Health share price has been on a roller coaster ride over the past year. The stock is up almost 50% from its 52-week low, but down 30% from its 52-week high. Despite the volatile share price, the company’s fundamentals are solid.
Sensyne Health is a clinical stage pharmaceutical company focused on developing digital therapeutics to treat serious chronic diseases. The company has a strong pipeline of products in development and partnerships with leading global healthcare companies. With the global market for digital therapeutics expected to grow rapidly in the coming years, Sensyne Health is well positioned to take advantage of this growing market.
